Treatment of choroidal neovascularization in a case of factor VIII deficiency: Ten-year follow-up

oc000085 10.3205/oc000085 urn:nbn:de:0183-oc0000855 Case Report Treatment of choroidal neovascularization in a case of factor VIII deficiency: Ten-year follow-up Rishi Rishi Pukhraj P MS, FRCS

Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, 18 College Road, Chennai 600006, Tamil Nadu, India, Phone: +91(0)44-28271616Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, India

docrishi@yahoo.co.in author Rishi Rishi Ekta E

Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, India

author German Medical Science GMS Publishing House

Düsseldorf

610 20180222 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). 2193-1496 8 GMS Ophthalmology Cases GMS Ophthalmol Cases 03 An unusual case of choroidal neovascularization in a young female with factor VIII deficiency is presented. The treatment course lasted 23 m</PlainText></TextGroup>onths. A favourable treatment outcome with restoration of the original visual acuity was achieved. The eye remained stable until the last follow-up, 10 years following therapy. </Pgraph></Abstract> <TextBlock linked="yes" name="Case description"> <MainHeadline>Case description</MainHeadline><Pgraph>A 21-year-old female presented with complaints of seeing a black spot in front of the right eye associated with distortion of the central vision of one week duration. There was no history of trauma. Best-corrected visual acuity (BCVA) in both eyes was 20/20. Anterior segment examination was essentially normal in both eyes. Fundus examination of the right eye revealed a yellowish-gray subretinal lesion with subretinal fluid supero-temporal to the fovea and pigment epithelial detachment (Figure 1 <ImgLink imgNo="1" imgType="figure"/>). The lesion spared the fovea. Optic disc and retinal vasculature appeared normal and no vitreous cells were noted. Fundus examination of the left eye was normal. </Pgraph><Pgraph>The patient was a diagnosed case of factor VIII deficiency about a month back. Her coagulation profile and hemogram were normal. However, factor VIII – C level was 37.5% (Normal range 50–150%). Fundus fluorescein angiography (FFA) revealed a classic extrafoveal choroidal neovascular membrane (CNVM) (Figure 1 <ImgLink imgNo="1" imgType="figure"/>). Focal laser photocoagulation to the CNVM was done after discussing the treatment options with the patient. The patient reported after 6 weeks with visual acuity in the right eye 20/30, N6. Clinical examination revealed a regressing extrafoveal neovascular component and an active juxtafoveal neovascular component. Clinical findings were confirmed on FFA and optical coherence tomography (OCT) (Figure 2 <ImgLink imgNo="2" imgType="figure"/>). The patient was treated with photodynamic therapy (PDT) followed by intravitreal triamcinolone acetonide (IVTA) injection (4 mg/0.1 ml) 2 days later. After 6 weeks, visual acuity in the right eye was 20/30 and the intraocular pressure (IOP) was 32 mmHg. Topical Timolol maleate 0.5% twice a day was started. Since there was persistent hyperfluorescence related to the extrafoveal CNVM, thermal laser photocoagulation was done. </Pgraph><Pgraph>With treatment, IOP came down to 12 mmHg in 2 weeks and the same treatment was continued. On the next visit eight weeks later, visual acuity was 20/60, N10. Clinical examination revealed recurrence of the juxtafoveal choroidal neovascular membrane, which was confirmed on FFA and OCT. The patient was treated with four intravitreal injections of bevacizumab (1.25 mg/0.05 ml) at an interval of 4–6 weeks. The IOP was found to have normalized and hence topical antiglaucoma treatment was stopped. </Pgraph><Pgraph>Six weeks after the fourth injection, visual acuity in the right eye improved to 20/30, N6. CNVM appeared scarred (Figure 3 <ImgLink imgNo="3" imgType="figure"/>). However, there was persistent leakage on FFA. The patient was treated with a combination of PDT and intravitreal bevacizumab. After 7 weeks, visual acuity improved to 20/20. Clinically, CNVM appeared scarred. The patient was followed up at intervals of 2 weeks. Fourteen weeks later, the patient reported with an increase in distortion in the right eye. BCVA was 20/20 in the right eye. OCT showed subretinal fluid and FFA showed recurrent extrafoveal CNVM. The patient was treated with intravitreal bevacizumab (1.25 mg/0.05 ml). The patient was seen six weeks later when she reported resolution of symptoms; her visual acuity was 20/20. Clinical findings were confirmed on OCT and FFA (Figure 4 <ImgLink imgNo="4" imgType="figure"/>). When seen last (i.e. 10 years post bevacizumab injection), BCVA was maintained at 20/20 and the fundus remained stable. </Pgraph></TextBlock> <TextBlock linked="yes" name="Discussion"> <MainHeadline>Discussion</MainHeadline><Pgraph>Various ophthalmic complications of coagulation disorder<TextGroup><PlainText>s h</PlainText></TextGroup>ave been described. Rubenstein et al. reviewed <TextGroup><PlainText>123 h</PlainText></TextGroup>emophiliacs, in which ocular complications such as subconjunctival hemorrhage, orbital or postoperative hemorrhage were noted in 25 patients <TextLink reference="1"></TextLink>. Maguluri e<TextGroup><PlainText>t a</PlainText></TextGroup>l. reported delayed suprachoroidal hemorrhage in a patient of mild factor VIII deficiency <TextLink reference="2"></TextLink>. Vitreous hemorrhage, pre- and subretinal hemorrhage have also been reported in 2 patients of von Willebrand’s factor deficiency <TextLink reference="3"></TextLink>. Hereby we report a case of choroidal neovascularization and its treatment in a known patient of factor VIII deficiency that resolved after a protracted and varied treatment course with restoration of the original visual acuity. </Pgraph></TextBlock> <TextBlock linked="yes" name="Notes"> <MainHeadline>Notes</MainHeadline><SubHeadline>Competing interests</SubHeadline><Pgraph>The authors declare that they have no competing interests.</Pgraph></TextBlock> <References linked="yes"> <Reference refNo="1"> <RefAuthor>Rubenstein RA</RefAuthor> <RefAuthor>Albert DM</RefAuthor> <RefAuthor>Scheie HG</RefAuthor> <RefTitle>Ocular complications of hemophilia</RefTitle> <RefYear>1966</RefYear> <RefJournal>Arch Ophthalmol</RefJournal> <RefPage>231-2</RefPage> <RefTotal>Rubenstein RA, Albert DM, Scheie HG. Ocular complications of hemophilia. Arch Ophthalmol. 1966 Aug;76(2):231-2. DOI: 10.1001/archopht.1966.03850010232014</RefTotal> <RefLink>http://dx.doi.org/10.1001/archopht.1966.03850010232014</RefLink> </Reference> <Reference refNo="2"> <RefAuthor>Maguluri S</RefAuthor> <RefAuthor>Bueno CL</RefAuthor> <RefAuthor>Fuller IB</RefAuthor> <RefAuthor>Eagle RC Jr</RefAuthor> <RefAuthor>Spell DW</RefAuthor> <RefTitle>Delayed suprachoroidal hemorrhage and factor VIII deficiency</RefTitle> <RefYear>2005</RefYear> <RefJournal>Am J Ophthalmol</RefJournal> <RefPage>195-7</RefPage> <RefTotal>Maguluri S, Bueno CL, Fuller IB, Eagle RC Jr, Spell DW. Delayed suprachoroidal hemorrhage and factor VIII deficiency. Am J Ophthalmol. 2005 Jan;139(1):195-7. DOI: 10.1016/j.ajo.2004.07.005</RefTotal> <RefLink>http://dx.doi.org/10.1016/j.ajo.2004.07.005</RefLink> </Reference> <Reference refNo="3"> <RefAuthor>Shiono T</RefAuthor> <RefAuthor>Abe S</RefAuthor> <RefAuthor>Watabe T</RefAuthor> <RefAuthor>Noro M</RefAuthor> <RefAuthor>Tamai M</RefAuthor> <RefAuthor>Akutsu Y</RefAuthor> <RefAuthor>Ishikawa M</RefAuthor> <RefAuthor>Suzuki S</RefAuthor> <RefAuthor>Mori K</RefAuthor> <RefTitle>Vitreous, retinal and subretinal hemorrhages associated with von Willebrand’s syndrome</RefTitle> <RefYear>1992</RefYear> <RefJournal>Graefes Arch Clin Exp Ophthalmol</RefJournal> <RefPage>496-7</RefPage> <RefTotal>Shiono T, Abe S, Watabe T, Noro M, Tamai M, Akutsu Y, Ishikawa M, Suzuki S, Mori K. Vitreous, retinal and subretinal hemorrhages associated with von Willebrand’s syndrome. Graefes Arch Clin Exp Ophthalmol. 1992;230(5):496-7. DOI: 10.1007/BF00175940</RefTotal> <RefLink>http://dx.doi.org/10.1007/BF00175940</RefLink> </Reference> </References> <Media> <Tables> <NoOfTables>0</NoOfTables> </Tables> <Figures> <Figure format="png" height="305" width="982"> <MediaNo>1</MediaNo> <MediaID>1</MediaID> <Caption><Pgraph><Mark1>Figure 1: Color photo, early and late images of FFA and OCT picture at baseline</Mark1></Pgraph></Caption> </Figure> <Figure format="png" height="275" width="989"> <MediaNo>2</MediaNo> <MediaID>2</MediaID> <Caption><Pgraph><Mark1>Figure 2: After PDT + IVTA. Persistent leakage from extrafoveal component, OCT shows absence of subretinal fluid.</Mark1></Pgraph></Caption> </Figure> <Figure format="png" height="275" width="986"> <MediaNo>3</MediaNo> <MediaID>3</MediaID> <Caption><Pgraph><Mark1>Figure 3: FFA and OCT findings after 4</Mark1><Mark1><Superscript>th</Superscript></Mark1><Mark1> Injection of bevacizumab. FFA shows late leakage, no subretinal fluid detected on OCT.</Mark1></Pgraph></Caption> </Figure> <Figure format="png" height="290" width="990"> <MediaNo>4</MediaNo> <MediaID>4</MediaID> <Caption><Pgraph><Mark1>Figure 4: Findings on FFA and OCT at last visit. Staining of the scar is seen on FFA, no subretinal fluid visible on OCT.</Mark1></Pgraph></Caption> </Figure> <NoOfPictures>4</NoOfPictures> </Figures> <InlineFigures> <NoOfPictures>0</NoOfPictures> </InlineFigures> <Attachments> <NoOfAttachments>0</NoOfAttachments> </Attachments> </Media> </OrigData> </GmsArticle>